GlassScriptPhysician profile
Anna T Dobracki
NPI 1093763153
$2,352.37
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $503 · 2020: $350 · 2021: $695 · 2022: $636 · 2023: $169.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $169.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $541.36 | 2019-2023 | Nucala, Trelegy Ellipta |
| Kaleo, INC. | $455.50 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $309.12 | 2019-2023 | Tezspire |
| Genzyme Corporation | $265.72 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $179.58 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $77.79 | 2019-2022 | |
| Genentech USA, INC. | $77.39 | 2020-2023 | Xolair |
| Pfizer INC. | $69.67 | 2019-2021 | |
| Aimmune Therapeutics, INC. | $66.26 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $53.23 | 2019-2023 | |
| Optinose US, INC. | $47.92 | 2019-2023 | |
| Uswm, LLC | $46.73 | 2021 | |
| Amgen INC. | $33.80 | 2021-2022 | |
| Vyera Pharmaceuticals, LLC | $30.05 | 2019 | |
| Biocryst US Sales Co., LLC | $26.55 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharming Healthcare, INC. | $18.72 | 2019 | |
| Mylan Specialty L.P. | $18.66 | 2021 | |
| Merck Sharp & Dohme LLC | $17.50 | 2021 | |
| Alk-Abello, INC | $16.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Dobracki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.